AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
阿豆学长长ov
发表于 2023-12-26 19:02:07
256
0
0
On December 26th, AstraZeneca announced that it had signed a final agreement on its acquisition proposal for Genxi Biotechnology. This proposed acquisition will add GC012F CAR-T cell therapy to AstraZeneca's cell therapy pipeline, further deepening its layout in the field of cell therapy.
AstraZeneca introduced that GC012F, based on the FasTCAR technology platform, is an innovative BCMA/CD19 dual target autochimeric antigen receptor T cell therapy (CAR-T) in the clinical stage, which is expected to become a new generation treatment plan for multiple myeloma, other types of malignant hematological tumors, and autoimmune diseases (including systemic lupus erythematosus (SLE)).
It is reported that the principle of autologous CAR-T cell therapy is to re edit and modify the patient's own immune T cells to target pathogenic cells for disease treatment. The production and preparation process is complex and time-consuming. The FasTCAR next-day production technology platform of Genxi Biotechnology can not only significantly shorten production time, but also enhance the health status of T cells, which is expected to improve the effectiveness of autologous CAR-T therapy. This technology is also expected to be applied in the treatment of rare diseases in the future.
AstraZeneca's Global Executive Vice President and Head of Research and Development in the Field of Cancer Therapy, Gao Shucan, stated that the company has established CAR-T and TCR-T pipelines for solid tumors. The acquisition of Genxi Biotechnology will further strengthen AstraZeneca's strength in the field of cell therapy. GC012F will help the company accelerate its strategy of laying out cell therapy in the field of blood tumors, and is expected to provide potential treatment options for blood tumor patients with similar differentiated production.
After the acquisition is completed, Genxi Biotechnology will continue to operate as a wholly-owned subsidiary of AstraZeneca in China and the United States.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
- Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy"
- Cancer company Aravive's US stock market plummeted by over 57% before trading
- Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA
- 12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China
- Baishime Squibb CAR-T therapy approved by the US FDA
- GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏